ライフサイエンスコーパス: antiviral

1 this nucleotide analogue as a direct-acting antiviral.

2 failure in clinical trials of direct-acting antivirals.

3 immune protection, and down-select candidate antivirals.

4 erve as novel targets for the development of antivirals.

5 llular functions potential targets for novel antivirals.

6 ), antibiotics (74%), tocilizumab (13%), and antivirals (14%).

7 ly effective vaccines to generate protective antiviral Ab responses.

8 Antiviral Abs were measured by ELISA.

9 responsible for their demonstrated in vitro antiviral activities against COVID-19.

10 ulate lung inflammation but it has no direct antiviral activity against ECTV.

11 vel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV-1(HXB2), with a half maxi

12 upted IFITM3 oligomerization and reduced its antiviral activity against Influenza A virus.

13 RDV shows broad-spectrum antiviral activity against RNA viruses, and previous stu

14 Investigations of antiviral activity against the human respiratory syncyti

15 n structure of HBV RNA was important for its antiviral activity and cleaved by MCPIP1 in the cell-fre

16 nto an antibody combination that potentiates antiviral activity and is able to prevent EVD in nonhuma

17 IRF3 activation, interferon production, and antiviral activity are compromised in cell cultures and

18 rferon-stimulated gene with well-established antiviral activity but limited mechanistic understanding

19 Molecular docking of analogues that retained antiviral activity demonstrated a relationship between p

20 Strikingly, antiviral activity in infected chicken cells, accompanie

21 e-dependent pharmacokinetics, and had potent antiviral activity in patients with CHB.

22 HPV16) infection in vitro and maintain their antiviral activity in vivo, while the glycooligomers exe

23 In this study, we assessed the influenza antiviral activity of 10 compounds previously shown to i

24 dels have been extensively used to study the antiviral activity of IFIT (interferon-induced protein w

25 Despite this promise, the antiviral activity of ivermectin has not been consistent

26 In this study, we examined the antiviral activity of natural compounds against the foll

27 The antiviral activity of nucleoside reverse transcriptase i

28 The antiviral activity of the eight identified compounds aga

29 irming that resistance was due to the direct antiviral activity of the IFN response.

30 -1 accessory protein Nef can antagonize this antiviral activity of TIM-1 while host restriction facto

31 via a structure-based approach and performed antiviral activity screening to identify compounds 29 an

32 that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro.

33 Translation of in vitro antiviral activity to the in vivo setting is crucial to

34 Target exposures were reached and antiviral activity was observed.

35 ecurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested,

36 Besides its antiviral activity, chloroquine might also mitigate the

37 to determine the molecular mechanisms of its antiviral activity, we show that PG specifically inhibit

38 disrupt membrane integrity but with no known antiviral activity, were tested for the ability to inhib

39 Some ISGs have specific antiviral activity, whereas others regulate the cellular

40 erpinning this unusual enzyme's wide-ranging antiviral activity.

41 ing affinity with a concomitant reduction in antiviral activity.

42 nhibition of JAK activity contributes to its antiviral activity.

43 f literature suggesting ivermectin has broad antiviral activity.

44 ith the treatment appear to be important for antiviral activity.

45 f the CpG in the viral genome determines its antiviral activity.IMPORTANCE Some RNA virus genomes are

46 ques in human brains, and treatment with the antiviral acyclovir (ACV) was reported to block the accu

47 t regulator of the sheddase, ADAM17, and the antiviral adaptor protein, stimulator of IFN genes.

48 Influenza vaccination and antiviral administration could be increased in both IC a

49 ing this kinase in developing small-molecule antivirals against SARS-CoV-2.

50 Remdesivir (RDV) is a direct-acting antiviral agent that is used to treat patients with seve

51 dies in both populations is the need for new antiviral agents and the necessity for combination thera

52 Anticoagulation and antiviral agents are standard treatments for DIC but are

53 While antiviral agents provide effective prophylaxis, there ar

54 ng the possibility to develop broad-spectrum antiviral agents targeting host factors.

55 n multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin.

56 With the advent of direct-acting antiviral agents, there has been a rapid rise in hepatit

57 ly no approved treatments with direct-acting antiviral agents.

58 ected neurons, as well as in the presence of antivirals alone.

59 signaling pathways, essential for respective antiviral and antibacterial responses, is common in prev

60 iptase inhibitors (NRTIs) are widely used as antiviral and anticancer agents, although they require i

61 institution of aggressive intensive care and antiviral and immune treatment to reduce the complicatio

62 Initial high dose and extended taper of antiviral and steroid prophylaxis for MK in high-risk, v

63 es, DVGs may also be used therapeutically as antivirals and vaccine adjuvants.

64 g for HCC in persons at risk, treatment with antivirals, and an emerging role for immunotherapy in HC

65 ural products and pharmaceuticals, including antiviral, antibacterial, anticancer and cardiac drugs(6

66 Our results indicate that antiviral antibodies against SARS-CoV-2 did not decline

67 tralizing or cross-reactive non-neutralizing antiviral antibodies.

68 5 who were tested (91.1%) were seropositive; antiviral antibody titers assayed by two pan-Ig assays i

69 They combat pathogens due to their antiviral, antifungal and antibacterial properties, and

70 , accompanied by suppression of IFN-mediated antiviral, apoptotic, and inflammatory functions, during

71 recognition specificity by a broad-spectrum antiviral aptamer, and they open new possibilities for a

72 demic virus for which Remdesivir is the only antiviral available.

73 he basis of lung disease and test immune and antiviral-based countermeasures.

74 ue chemical scaffolds and enhanced influenza antiviral capabilities.

75 nant CD4(+) T cell epitopes induced a robust antiviral CD4(+) T cell response in the cornea that was

76 HSCT) during chronic infection generated new antiviral CD8 T cells, despite sustained virus replicati

77 These findings confirm antiviral CD8(+) T cell exhaustion during SYMP herpes in

78 family member 5 (PGAM5) is important for the antiviral cellular response.

79 A-protein interactions to repurpose powerful antiviral chromatin silencing machinery for sex chromoso

80 resents a screenable process for identifying antiviral compounds effective against SARS-CoV-2.

81 Antiviral compounds exert one such pressure on virus pop

82 ogether, our results identified a new set of antiviral compounds for the potential treatment of influ

83 ntial and to generate effective vaccines and antiviral compounds.

84 e I interferon (IFN) system is important for antiviral control in the brain.

85 -Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition t

86 Direct-acting antiviral (DAA) therapy has transformed the management o

87 metabolic parameters early in direct-acting antiviral (DAA) therapy.

88 irological response (SVR) with direct-acting antiviral (DAA).

89 s a lack of data on the use of direct-acting antivirals (DAA) on the risk of death and tumoral recurr

90 limination by sofosbuvir-based direct-acting antivirals (DAAs) and addition of RBV improves NK cell f

91 The advent of direct-acting antivirals (DAAs) has transformed the landscape of hepat

92 d after viral eradication with direct acting antivirals (DAAs).

93 robust genetic signals relating to key host antiviral defence mechanisms and mediators of inflammato

94 PRRs) which are known to be involved in host antiviral defences.

95 llers, NK cells are also key helper cells in antiviral defense, influencing adaptive immune responses

96 ly controlled to ensure timely activation of antiviral defense.

97 important indication of their relevance for antiviral defense.

98 ighest viral loads and initial engagement of antiviral defenses are expected.

99 viruses is important in understanding innate antiviral defenses in birds.IMPORTANCE Birds are importa

100 exert effects on the host cell that promote antiviral defenses.

101 ell as effects on the host cell that enhance antiviral defenses.IMPORTANCE Kaposi's sarcoma-associate

102 s for replication and to avoid the litany of antiviral detection mechanisms in the cytoplasm remains

103 in addition to RNA cap and SAM pockets, for antiviral development.

104 provide potential anti-influenza targets for antiviral development.

105 cap methylation is an attractive target for antiviral discovery and development of new live attenuat

106 The APOBEC3 family of antiviral DNA cytosine deaminases is implicated as the s

107 ve care as background therapy, including the antiviral drug remdesivir and, when indicated, supplemen

108 The antiviral drug remdesivir, dexamethasone, transfusion of

109 ctions and facilitate future applications in antiviral drug research to manage flavivirus infections.

110 treatment failure upon standard care due to antiviral drug resistance and treatment-limiting side ef

111 he mammalian SKI complex as a broad-spectrum antiviral drug target and identifies lead compounds for

112 time, only one FDA-approved anti-SARS-CoV-2 antiviral drug, remdesivir, is available, and unfortunat

113 Some antiviral drugs and broadly reactive influenza vaccines

114 infection, to repurpose currently available antiviral drugs and to develop new therapies and vaccine

115 With limited antiviral drugs and vaccines available, vector control i

116 ins, is direly needed for the development of antiviral drugs and vaccines.

117 ; yet currently, no vaccines or FDA-approved antiviral drugs are available to counter these pathogens

118 national economies as effective vaccines or antiviral drugs are not currently available (according t

119 Because antiviral drugs can have side effects and show reduced c

120 ions that should facilitate the discovery of antiviral drugs for this important zoonotic pathogen.

121 al; however, small-molecule orally available antiviral drugs have yet to be developed.

122 Additionally, no antiviral drugs or vaccines were developed against the c

123 effect of glycans on the binding kinetics of antiviral drugs to the influenza neuraminidase.

124 There are no antiviral drugs with proven clinical efficacy for the tr

125 ional design of live attenuated vaccines and antiviral drugs.

126 ies are required to assess whether a similar antiviral effect is achievable in humans without toxic e

127 into the immune mechanisms that mediate this antiviral effect.

128 se subpopulations and their association with antiviral effector CD8+ T cell subsets were also charact

129 ultures that correlated with upregulation of antiviral effector genes.

130 ic individuals develop a higher frequency of antiviral effector memory CD4(+) T(EM) cells specific to

131 leus, and contributes to the upregulation of antiviral effectors in response to type I interferons.IM

132 s exhibit permanent, low-level expression of antiviral effectors that safely protect them from variou

133 y blocks NF-kappaB, likely to counteract its antiviral effects and promote efficient viral replicatio

134 infected cell surface, and LIF enhanced the antiviral effects of antibody.

135 To determine the extent to which antiviral effects of IRF-1 are B cell intrinsic, we gene

136 Here, we show that Vpr mitigates the antiviral effects of REAF, a protein highly expressed in

137 To assess antiviral effects, RSV RNA viral load from nasal swabs w

138 ed to induce both therapeutic and preventive antiviral effects.

139 t stem cells, and apilimod also demonstrated antiviral efficacy in a primary human lung explant model

140 The antiviral efficacy of many nucleoside analogues is stron

141 We therefore provide evidence for the antiviral efficacy of remdesivir in vivo, and its potent

142 K2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 ther

143 highlight an ever-evolving arms race between antiviral factors and viral pathogens and provide a new

144 Intriguingly, mRNAs encoding for antiviral factors bypass this translational shutoff, sug

145 ong antiviral response with up-regulation of antiviral factors such as OAS1-3 and IFIT1-3 and T helpe

146 Pimodivir is a first-in-class antiviral for influenza A under development for these pa

147 ates such a nano-inhibitor might be a potent antiviral for the treatment of influenza infection.

148 The antiviral function of EDAL resides in a 56-nt antiviral

149 is article provide further insights into the antiviral function of NK cells and the pathways involved

150 munotherapeutic strategies to increase their antiviral function.

151 bited characteristics associated with potent antiviral function: memory T cells secreted cytokines an

152 O(2) increased IAV replication and inhibited antiviral gene and protein expression in macrophages in

153 splenic viral burden and reduction in global antiviral gene pathways.

154 nalysis shows that ERBs upregulate canonical antiviral genes typical of mammalian systems, such as IS

155 ression of an array of interferon-stimulated antiviral genes, is a vital part of host defense.

156 in turn induce the expression of hundreds of antiviral genes.

157 And yet, no antivirals have been identified to treat astrovirus infe

158 compensates for the absence of apoptosis in antiviral host defense.

159 tory demyelination due to loss of protective antiviral host immunity.IMPORTANCE The current trend in

160 Antiviral human monoclonal antibodies (mAbs) are promisi

161 deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune

162 and IFN-gamma signaling pathways to optimize antiviral IFN-gamma activity.

163 in thus demonstrates that LY6E is a critical antiviral immune effector that controls CoV infection an

164 uitination of MAVS and thus shuts off innate antiviral immune response.

165 disease 2019 (COVID-19) severity, beneficial antiviral immune responses may be identified in detail.

166 st widespread 2'3'-cGAMP signaling in insect antiviral immunity and explain how a family of cGAS-STIN

167 Interferon (IFN)-Is are crucial mediators of antiviral immunity and homeostatic immune system regulat

168 Thus, symbiotic intestinal bacteria modulate antiviral immunity and levels of circulating alphaviruse

169 Type I interferon (IFN-I) provides effective antiviral immunity but can exacerbate harmful inflammato

170 Antibodies are typically thought to mediate antiviral immunity by blocking host-cell infection.

171 was associated with IFN-gamma signaling and antiviral immunity controlled by T cells (T(H)1 and CD8(

172 Antiviral immunity in insects is mediated by the RNA int

173 ating the mechanisms by which CHIKV subverts antiviral immunity to establish and maintain a persisten

174 3 and thus allows timely induction of innate antiviral immunity.

175 ferentiation that can be targeted to improve antiviral immunity.

176 FN-alpha, suggesting a potential weakness in antiviral immunity.

177 e principally recognized as key mediators of antiviral immunity.

178 NV impacting some, but not all, mediators of antiviral immunity.

179 Our work contributes to the field of antiviral immunology by discovering and characterizing a

180 ibavirin (PegIFN-RBV) plus one direct-acting antiviral in 53.4%, PegIFN-RBV in 34.5%, and sofosbuvir/

181 Including the effects of direct acting antivirals in our models, we found that in spite of decr

182 Licensed antivirals inhibit virus replication, but do not affect

183 ce could be exploited for the development of antiviral inhibitors.

184 antiviral signaling (MAVS) protein-dependent antiviral interferon (IFN) responses.

185 Vs are complex and regulated in part through antiviral interferons.

186 als, and humans, can lead to new targets for antiviral interventions.

187 of ZIKV NS5 as critical in the regulation of antiviral ISG and cell cycle responses that permit ZIKV

188 The antiviral lectin, Griffithsin (GRFT), has been shown to

189 ur results shed light on a potentially broad antiviral mechanism by 25HC through depleting accessible

190 The results have uncovered an antiviral mechanism through inhibitor-induced tetrameriz

191 striction by ZAP and whether CpGs have other antiviral mechanisms.

192 ity that targeting this cytokine may restore antiviral mechanisms.FUNDINGThis study was supported by

193 duction of type I interferons, which are key antiviral mediators, is reportedly blunted.

194 with paralogs MItochondrial STress Response AntiViral (MISTRAV) and/or MItochondrial STress Response

195 veloping highly selective and broad-spectrum antiviral molecules active against emerging and dangerou

196 and safely deployed, the rapidity with which antiviral monoclonal antibodies can be isolated and engi

197 ar among patients treated with DAA, IFN, and antiviral naive, respectively (P < 0.001).

198 capacity of herpesvirus mutants that trigger antiviral necroptotic cell death upon early viral gene e

199 aling a cell-extrinsic downregulation of the antiviral NK cell response by adrenergic neuroendocrine

200 , which functions as novel chain-terminating antiviral nucleotide when misincorporated by viral RNA-d

201 (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents.

202 There is no proven antiviral or immunomodulatory therapy for coronavirus di

203 However, no effective antivirals or vaccines are available.

204 is imperative to address this challenge, and antiviral peptides (AVPs) represent a valuable resource

205 5 binding to STAT2, disrupt the formation of antiviral PML-STAT2 NBs, and direct PML degradation.

206 esults are significant for the design of new antiviral prodrugs.

207 OI and DMF induce a distinct IFN-independent antiviral program that is broadly effective in limiting

208 Our findings reveal novel antiviral properties of PG, suggesting its high potentia

209 alganciclovir, 900 mg, daily for 100 days as antiviral prophylaxis (n = 105).

210 the use of preemptive therapy, compared with antiviral prophylaxis, resulted in a lower incidence of

211 ISG expression during infection that confers antiviral protection but minimizes disruption of intesti

212 ith the role of these receptors in mediating antiviral protection in various viral infections, necess

213 Tetherin/BST-2 is an antiviral protein that blocks the release of enveloped v

214 The antiviral protein ZAP binds viral RNA containing CpGs an

215 ual twist, human cytomegalovirus co-opts the antiviral radical SAM enzyme viperin (virus-inhibitory p

216 activation from latency.IMPORTANCE While HSV antivirals reduce the severity and duration of clinical

217 CTs of DAA therapy vs placebo or an outdated antiviral regimen, 48 other treatment studies, and 33 co

218 t in VEEV, the trajectory and penetration of antiviral resistance reflected the microenvironment in w

219 NK cells play an important role in antiviral resistance.

220 lymphocyte populations that are key for the antiviral response and immune reconstitution.FUNDINGNIH

221 is well tolerated and can induce a sustained antiviral response in WHV-infected woodchucks; the ident

222 Here, we addressed whether antiviral response of peripheral blood lymphocytes diffe

223 g early illness are indicators of an altered antiviral response potentially contributing to disease s

224 ole T cells play in the orchestration of the antiviral response underlying the pathogenesis of the di

225 In these animals, the antiviral response was maintained until the end of the s

226 SARS-CoV-2 induced a strong antiviral response with up-regulation of antiviral facto

227 ossmann fold domain(6), sculpting a powerful antiviral response(7-10) that can drive viruses to extin

228 mplex cellular networks activated during the antiviral response, placing IFN-stimulated genes in a fu

229 ction and are important in the host's innate antiviral response.

230 and viral RNA during the type VI CRISPR-Cas antiviral response.

231 t may have roles during the RNase L-mediated antiviral response.

232 Type I interferon (IFN) antiviral responses and SARS-CoV-2-specific T cell respo

233 sion of viral genes and activation of innate antiviral responses during infection result in an increa

234 ze nucleotide second messengers and initiate antiviral responses in bacterial and animal cells.

235 in ex vivo vaginal tissue cultures triggered antiviral responses in myeloid and CD4(+) T cells.

236 r, immunoglobulin G (IgG) can also stimulate antiviral responses through its constant region.

237 Rylating) PARPs are associated with cellular antiviral responses.

238 ies at the intersection of antibacterial and antiviral responses.

239 and IFN-gamma pathways in achieving optimal antiviral responses.IMPORTANCE IFN-alpha/beta induction

240 de compelling evidence for the regulation of antiviral RNAi by the jasmonate hormone signaling in pla

241 onse to the viral suppression of the primary antiviral RNAi immunity.

242 and eri-6/7-defective mutants because of an antiviral RNAi response to dsRNA.

243 ls enhances DCV replication independently of antiviral RNAi, and VINR-knockout adult flies exhibit en

244 While RSK2 displays an antiviral role, we demonstrate a virus-supportive functi

245 ease 2019 (COVID-19) serological testing and antiviral screening.

246 le gene I (RIG-I) and initiate mitochondrial antiviral signaling (MAVS) protein-dependent antiviral i

247 acid-inducible gene I (RIG-I)/mitochondrial antiviral signaling (MAVS)-dependent remodeling of the c

248 g lytic replication and inhibit a variety of antiviral signaling pathways.

249 er proteins, that this interaction modulates antiviral signaling via disruption of USP7 interactions

250 (PDE) domain to counteract RNase L-mediated antiviral signaling.

251 n limits CNS viral spread by establishing an antiviral state, but also promotes blood brain barrier i

252 overy sets HR3 as a new candidate target for antiviral strategies for NiV and likely for related viru

253 Efforts to develop antiviral strategies for treating MS are underway.

254 Antiviral strategies targeting early steps of infection

255 B12 inhibition as a promising broad-spectrum antiviral strategy for the treatment of Flaviviridae inf

256 factors upon which viruses rely as a viable antiviral strategy.

257 ntiviral function of EDAL resides in a 56-nt antiviral substructure through which its 18-nt helix-loo

258 ing host translational machinery and evading antiviral surveillance.

259 trix layer have not been available, impeding antiviral targeting and understanding of the pH-dependen

260 the viral life cycle that may be amenable to antiviral targeting as well as key features of its biolo

261 h purified proteins are crucial advances for antiviral targeting of influenza viruses.

262 04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infecti

263 l polymerases have been attractive and major antiviral therapeutic targets.

264 stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to limit morbidity

265 Without approved antiviral therapeutics or vaccines to this ongoing globa

266 s, which could facilitate the development of antiviral therapeutics targeting the CHIKV attachment st

267 urgent need for the accelerated discovery of antiviral therapeutics.

268 d RNA [(+)RNA] viruses, the major target for antiviral therapies is genomic RNA replication, which oc

269 The discovery of new antiviral therapies is imperative to address this challe

270 Ongoing trials are testing antiviral therapies, immune modulators, and anticoagulan

271 edge that may guide development of effective antiviral therapies.

272 % and few short-term harms relative to older antiviral therapies.

273 d the effective monitoring of the associated antiviral therapies.

274 to persist in individuals during combination antiviral therapy (ART).

275 virus (HCV) screening found interferon-based antiviral therapy associated with increased likelihood o

276 Based on 18 trials (n = 2972), antiviral therapy compared with placebo or no treatment

277 reduces the risk of HCC development, even if antiviral therapy fails to completely eliminate HCC risk

278 nce is a critical problem limiting effective antiviral therapy for HIV/AIDS.

279 adhere to frequent, consistent follow-up so antiviral therapy may begin at the earliest sign of reac

280 = 24 686) found inconsistent associations of antiviral therapy vs no therapy with risk of hepatocellu

281 An SVR after antiviral therapy was associated with decreased adjusted

282 R 1.07, 95% C.I. 1.02-1.13, p<0.01) and dual antiviral therapy(OR 12.46, 95% C.I. 2.09-74.20, p<0.1)

283 Cohort A: After 3 years of antiviral therapy, 33% and 30% had detectable HBcrAg and

284 basal QTc values, basal heart rate and dual antiviral therapy, age(OR 1.06, 95% C.I. 1.00-1.13, p<0.

285 ge, baseline viral load, vaccination status, antiviral therapy, and emergence of drug resistance on v

286 e been sought as novel molecular targets for antiviral therapy.

287 se functionalities, represent a milestone in antiviral therapy.

288 espite combination systemic and intravitreal antiviral therapy; however, none of the 19 patients demo

289 cterized according to age; sex; comorbidity; antiviral therapy; viral load, expressed as cycle thresh

290 This assay may help identify novel antivirals to control the COVID-19 pandemic.

291 om direct effector function to regulation of antiviral transcription.

292 remains a barrier to accessing direct-acting antiviral treatment (DAA) for hepatitis C virus (HCV) in

293 lowed by 400 mg once daily for 6 days) or no antiviral treatment (not-placebo controlled).

294 diagnosis can help initiate early effective antiviral treatment and isolation.

295 NA level >=1250 IU/mL, CMV viremia requiring antiviral treatment, or end-organ disease), nonrelapse m

296 wn, the formulation of strategies concerning antiviral treatment, vaccination, and epidemiological co

297 28 patients (21.4%) had previously undergone antiviral treatment.

298 eta complexed with nucleic acids triggers an antiviral type I interferon response in neuroglia, resul

299 assay to engineer stabilized GP variants for antiviral vaccines and to discover and improve drugs tha

300 ultures infected with HSV-1, with or without antivirals, were assessed for Abeta and p-tau expression